CA2824997C - Compositions and methods for treating cancer - Google Patents

Info

Publication number

CA2824997C

CA2824997C CA2824997A CA2824997A CA2824997C CA 2824997 C CA2824997 C CA 2824997C CA 2824997 A CA2824997 A CA 2824997A CA 2824997 A CA2824997 A CA 2824997A CA 2824997 C CA2824997 C CA 2824997C

Authority

CA

Canada

Prior art keywords

cells

cell

car

tumor

nucleic acid

Prior art date

2011-01-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims description 301
• 201000011510 cancer Diseases 0.000 title claims description 64
• 238000000034 method Methods 0.000 title abstract description 68
• 239000000203 mixture Substances 0.000 title abstract description 34
• 230000027455 binding Effects 0.000 claims abstract description 64
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims abstract description 45
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims abstract description 45
• 230000000139 costimulatory effect Effects 0.000 claims abstract description 39
• 108020003175 receptors Proteins 0.000 claims abstract description 21
• 229940014144 folate Drugs 0.000 claims abstract description 11
• 239000011724 folic acid Substances 0.000 claims abstract description 11
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 288
• 239000000427 antigen Substances 0.000 claims description 163
• 108091007433 antigens Proteins 0.000 claims description 159
• 102000036639 antigens Human genes 0.000 claims description 159
• 150000007523 nucleic acids Chemical class 0.000 claims description 122
• 230000011664 signaling Effects 0.000 claims description 102
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 86
• 102000039446 nucleic acids Human genes 0.000 claims description 43
• 108020004707 nucleic acids Proteins 0.000 claims description 43
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
• 102000005962 receptors Human genes 0.000 claims description 20
• 239000012634 fragment Substances 0.000 claims description 12
• 230000036210 malignancy Effects 0.000 claims description 6
• 210000001744 T-lymphocyte Anatomy 0.000 abstract description 438
• 206010033128 Ovarian cancer Diseases 0.000 abstract description 63
• 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 62
• 210000004027 cell Anatomy 0.000 description 453
• 239000013598 vector Substances 0.000 description 184
• 241000699670 Mus sp. Species 0.000 description 119
• 108090000623 proteins and genes Proteins 0.000 description 97
• 238000001727 in vivo Methods 0.000 description 69
• 230000014509 gene expression Effects 0.000 description 67
• 238000001802 infusion Methods 0.000 description 66
• 230000002688 persistence Effects 0.000 description 55
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 51
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 51
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 49
• 102000004169 proteins and genes Human genes 0.000 description 47
• 239000000047 product Substances 0.000 description 46
• 238000002347 injection Methods 0.000 description 45
• 239000007924 injection Substances 0.000 description 45
• 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 44
• 108020004414 DNA Proteins 0.000 description 44
• 230000004044 response Effects 0.000 description 44
• 238000012546 transfer Methods 0.000 description 42
• 230000000259 anti-tumor effect Effects 0.000 description 41
• 238000011282 treatment Methods 0.000 description 41
• 239000011324 bead Substances 0.000 description 40
• 201000010099 disease Diseases 0.000 description 37
• 108090000765 processed proteins & peptides Proteins 0.000 description 36
• 230000000694 effects Effects 0.000 description 33
• 238000003556 assay Methods 0.000 description 32
• 230000001086 cytosolic effect Effects 0.000 description 32
• 238000000338 in vitro Methods 0.000 description 32
• 238000004519 manufacturing process Methods 0.000 description 32
• 210000004369 blood Anatomy 0.000 description 31
• 239000008280 blood Substances 0.000 description 31
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 30
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 30
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 30
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 30
• 241001465754 Metazoa Species 0.000 description 29
• 230000003902 lesion Effects 0.000 description 29
• 230000006870 function Effects 0.000 description 28
• 210000004881 tumor cell Anatomy 0.000 description 28
• 150000002632 lipids Chemical class 0.000 description 25
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 24
• 238000007912 intraperitoneal administration Methods 0.000 description 24
• 239000002245 particle Substances 0.000 description 24
• 102000004196 processed proteins & peptides Human genes 0.000 description 24
• 210000001519 tissue Anatomy 0.000 description 24
• 230000004083 survival effect Effects 0.000 description 23
• -1 ICOS Proteins 0.000 description 22
• 239000003446 ligand Substances 0.000 description 22
• 238000010361 transduction Methods 0.000 description 22
• 230000026683 transduction Effects 0.000 description 22
• 102000004127 Cytokines Human genes 0.000 description 21
• 108090000695 Cytokines Proteins 0.000 description 21
• 239000003795 chemical substances by application Substances 0.000 description 21
• 241000699666 Mus <mouse, genus> Species 0.000 description 20
• 230000000638 stimulation Effects 0.000 description 20
• 108700019146 Transgenes Proteins 0.000 description 19
• 230000003834 intracellular effect Effects 0.000 description 19
• 210000002966 serum Anatomy 0.000 description 19
• 230000028993 immune response Effects 0.000 description 18
• 229920001184 polypeptide Polymers 0.000 description 18
• 108091008874 T cell receptors Proteins 0.000 description 17
• 230000004913 activation Effects 0.000 description 17
• 239000012636 effector Substances 0.000 description 17
• 238000002474 experimental method Methods 0.000 description 17
• 239000002773 nucleotide Substances 0.000 description 17
• 125000003729 nucleotide group Chemical group 0.000 description 17
• 108091033319 polynucleotide Proteins 0.000 description 17
• 102000040430 polynucleotide Human genes 0.000 description 17
• 239000002157 polynucleotide Substances 0.000 description 17
• 230000004614 tumor growth Effects 0.000 description 17
• 241000713666 Lentivirus Species 0.000 description 16
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 16
• 210000004698 lymphocyte Anatomy 0.000 description 16
• 239000000463 material Substances 0.000 description 16
• 230000004936 stimulating effect Effects 0.000 description 16
• 238000011194 good manufacturing practice Methods 0.000 description 15
• 230000001965 increasing effect Effects 0.000 description 15
• 210000005259 peripheral blood Anatomy 0.000 description 15
• 239000011886 peripheral blood Substances 0.000 description 15
• 239000013612 plasmid Substances 0.000 description 15
• 238000012360 testing method Methods 0.000 description 15
• 238000002560 therapeutic procedure Methods 0.000 description 15
• 229940024606 amino acid Drugs 0.000 description 14
• 150000001413 amino acids Chemical class 0.000 description 14
• 230000010261 cell growth Effects 0.000 description 14
• 239000002502 liposome Substances 0.000 description 14
• 230000002354 daily effect Effects 0.000 description 13
• 210000004072 lung Anatomy 0.000 description 13
• 239000000243 solution Substances 0.000 description 13
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 12
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 12
• 150000001875 compounds Chemical class 0.000 description 12
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
• 239000003814 drug Substances 0.000 description 12
• 239000013604 expression vector Substances 0.000 description 12
• 230000002601 intratumoral effect Effects 0.000 description 12
• 206010003445 Ascites Diseases 0.000 description 11
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 11
• 241000700605 Viruses Species 0.000 description 11
• 210000003719 b-lymphocyte Anatomy 0.000 description 11
• 238000005415 bioluminescence Methods 0.000 description 11
• 230000029918 bioluminescence Effects 0.000 description 11
• 230000015572 biosynthetic process Effects 0.000 description 11
• 230000037396 body weight Effects 0.000 description 11
• 230000001413 cellular effect Effects 0.000 description 11
• 230000007423 decrease Effects 0.000 description 11
• 208000035475 disorder Diseases 0.000 description 11
• 229940079593 drug Drugs 0.000 description 11
• 238000011081 inoculation Methods 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
• 235000011089 carbon dioxide Nutrition 0.000 description 10
• 230000004068 intracellular signaling Effects 0.000 description 10
• 238000001990 intravenous administration Methods 0.000 description 10
• 239000000523 sample Substances 0.000 description 10
• 238000007920 subcutaneous administration Methods 0.000 description 10
• 238000013518 transcription Methods 0.000 description 10
• 230000035897 transcription Effects 0.000 description 10
• 239000013603 viral vector Substances 0.000 description 10
• 108010002350 Interleukin-2 Proteins 0.000 description 9
• 102000000588 Interleukin-2 Human genes 0.000 description 9
• 241000124008 Mammalia Species 0.000 description 9
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
• 238000013459 approach Methods 0.000 description 9
• 238000011161 development Methods 0.000 description 9
• 230000018109 developmental process Effects 0.000 description 9
• 230000012010 growth Effects 0.000 description 9
• 238000003384 imaging method Methods 0.000 description 9
• 238000010172 mouse model Methods 0.000 description 9
• 230000036961 partial effect Effects 0.000 description 9
• 208000037821 progressive disease Diseases 0.000 description 9
• 238000011160 research Methods 0.000 description 9
• 230000001177 retroviral effect Effects 0.000 description 9
• 230000003612 virological effect Effects 0.000 description 9
• 201000009030 Carcinoma Diseases 0.000 description 8
• 206010027476 Metastases Diseases 0.000 description 8
• 108700008625 Reporter Genes Proteins 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 239000000872 buffer Substances 0.000 description 8
• 238000002659 cell therapy Methods 0.000 description 8
• 230000009089 cytolysis Effects 0.000 description 8
• 230000001419 dependent effect Effects 0.000 description 8
• 238000000684 flow cytometry Methods 0.000 description 8
• 239000005090 green fluorescent protein Substances 0.000 description 8
• 238000003306 harvesting Methods 0.000 description 8
• 230000001976 improved effect Effects 0.000 description 8
• 238000010348 incorporation Methods 0.000 description 8
• 230000004807 localization Effects 0.000 description 8
• 230000007774 longterm Effects 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 206010061289 metastatic neoplasm Diseases 0.000 description 8
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
• 230000028327 secretion Effects 0.000 description 8
• 210000002700 urine Anatomy 0.000 description 8
• 241000283707 Capra Species 0.000 description 7
• 241000725303 Human immunodeficiency virus Species 0.000 description 7
• 108060003951 Immunoglobulin Proteins 0.000 description 7
• 238000002617 apheresis Methods 0.000 description 7
• 238000002512 chemotherapy Methods 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 102000018358 immunoglobulin Human genes 0.000 description 7
• 230000001939 inductive effect Effects 0.000 description 7
• 208000015181 infectious disease Diseases 0.000 description 7
• 238000004806 packaging method and process Methods 0.000 description 7
• 230000002085 persistent effect Effects 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 230000001105 regulatory effect Effects 0.000 description 7
• 239000011780 sodium chloride Substances 0.000 description 7
• 230000001988 toxicity Effects 0.000 description 7
• 231100000419 toxicity Toxicity 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
• 206010000060 Abdominal distension Diseases 0.000 description 6
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 6
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 6
• 206010027458 Metastases to lung Diseases 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
• 238000004113 cell culture Methods 0.000 description 6
• 108700010039 chimeric receptor Proteins 0.000 description 6
• 229940109239 creatinine Drugs 0.000 description 6
• 229960004397 cyclophosphamide Drugs 0.000 description 6
• 230000008029 eradication Effects 0.000 description 6
• 238000011156 evaluation Methods 0.000 description 6
• 230000002147 killing effect Effects 0.000 description 6
• 210000000265 leukocyte Anatomy 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 230000009401 metastasis Effects 0.000 description 6
• 230000001394 metastastic effect Effects 0.000 description 6
• 238000012544 monitoring process Methods 0.000 description 6
• 230000035755 proliferation Effects 0.000 description 6
• 230000010076 replication Effects 0.000 description 6
• 230000032258 transport Effects 0.000 description 6
• 241001430294 unidentified retrovirus Species 0.000 description 6
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 5
• 101001130286 Homo sapiens Rab GTPase-binding effector protein 2 Proteins 0.000 description 5
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
• 102100023123 Mucin-16 Human genes 0.000 description 5
• 206010061309 Neoplasm progression Diseases 0.000 description 5
• 108010038807 Oligopeptides Proteins 0.000 description 5
• 102000015636 Oligopeptides Human genes 0.000 description 5
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 5
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 5
• 102100038358 Prostate-specific antigen Human genes 0.000 description 5
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
• 230000005867 T cell response Effects 0.000 description 5
• 241000021375 Xenogenes Species 0.000 description 5
• 230000002411 adverse Effects 0.000 description 5
• 230000005809 anti-tumor immunity Effects 0.000 description 5
• 230000005875 antibody response Effects 0.000 description 5
• 238000001574 biopsy Methods 0.000 description 5
• 210000001185 bone marrow Anatomy 0.000 description 5
• 239000011575 calcium Substances 0.000 description 5
• 229910052791 calcium Inorganic materials 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 230000002596 correlated effect Effects 0.000 description 5
• 229940000406 drug candidate Drugs 0.000 description 5
• 229960000390 fludarabine Drugs 0.000 description 5
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 5
• 238000001415 gene therapy Methods 0.000 description 5
• 239000008103 glucose Substances 0.000 description 5
• 239000003102 growth factor Substances 0.000 description 5
• 239000001963 growth medium Substances 0.000 description 5
• 230000036541 health Effects 0.000 description 5
• 102000051894 human RABEP2 Human genes 0.000 description 5
• 210000005260 human cell Anatomy 0.000 description 5
• 230000003053 immunization Effects 0.000 description 5
• 238000002649 immunization Methods 0.000 description 5
• 238000011534 incubation Methods 0.000 description 5
• 230000036512 infertility Effects 0.000 description 5
• 238000003780 insertion Methods 0.000 description 5
• 230000037431 insertion Effects 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 238000010253 intravenous injection Methods 0.000 description 5
• 230000005291 magnetic effect Effects 0.000 description 5
• 239000002953 phosphate buffered saline Substances 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 210000004986 primary T-cell Anatomy 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 238000012429 release testing Methods 0.000 description 5
• 238000012216 screening Methods 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 230000005751 tumor progression Effects 0.000 description 5
• 241000701161 unidentified adenovirus Species 0.000 description 5
• PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 4
• 108010082126 Alanine transaminase Proteins 0.000 description 4
• 108010088751 Albumins Proteins 0.000 description 4
• 102000009027 Albumins Human genes 0.000 description 4
• 102100023635 Alpha-fetoprotein Human genes 0.000 description 4
• 102000006306 Antigen Receptors Human genes 0.000 description 4
• 108010083359 Antigen Receptors Proteins 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• 206010006187 Breast cancer Diseases 0.000 description 4
• 208000026310 Breast neoplasm Diseases 0.000 description 4
• 102100037904 CD9 antigen Human genes 0.000 description 4
• 241000701022 Cytomegalovirus Species 0.000 description 4
• 241000702421 Dependoparvovirus Species 0.000 description 4
• 206010061818 Disease progression Diseases 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
• 102000004388 Interleukin-4 Human genes 0.000 description 4
• 108090000978 Interleukin-4 Proteins 0.000 description 4
• 108060001084 Luciferase Proteins 0.000 description 4
• 239000005089 Luciferase Substances 0.000 description 4
• 108010052285 Membrane Proteins Proteins 0.000 description 4
• 206010051676 Metastases to peritoneum Diseases 0.000 description 4
• 102100027378 Prothrombin Human genes 0.000 description 4
• 108010094028 Prothrombin Proteins 0.000 description 4
• 108010000499 Thromboplastin Proteins 0.000 description 4
• 102100030859 Tissue factor Human genes 0.000 description 4
• 230000035508 accumulation Effects 0.000 description 4
• 238000009825 accumulation Methods 0.000 description 4
• 230000001464 adherent effect Effects 0.000 description 4
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 4
• 210000000612 antigen-presenting cell Anatomy 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 230000006037 cell lysis Effects 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 238000010276 construction Methods 0.000 description 4
• 231100000135 cytotoxicity Toxicity 0.000 description 4
• 230000003013 cytotoxicity Effects 0.000 description 4
• 238000013480 data collection Methods 0.000 description 4
• 230000003111 delayed effect Effects 0.000 description 4
• 230000005750 disease progression Effects 0.000 description 4
• 239000003792 electrolyte Substances 0.000 description 4
• 230000012953 feeding on blood of other organism Effects 0.000 description 4
• 108020005243 folate receptor Proteins 0.000 description 4
• 102000006815 folate receptor Human genes 0.000 description 4
• 238000001476 gene delivery Methods 0.000 description 4
• 238000009169 immunotherapy Methods 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 208000032839 leukemia Diseases 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 239000000693 micelle Substances 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 208000010918 peritoneal neoplasm Diseases 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 229940039716 prothrombin Drugs 0.000 description 4
• 230000006798 recombination Effects 0.000 description 4
• 238000005215 recombination Methods 0.000 description 4
• 230000003362 replicative effect Effects 0.000 description 4
• 238000010839 reverse transcription Methods 0.000 description 4
• 230000009870 specific binding Effects 0.000 description 4
• 230000002269 spontaneous effect Effects 0.000 description 4
• 210000000130 stem cell Anatomy 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 239000003981 vehicle Substances 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 3
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
• 102100027207 CD27 antigen Human genes 0.000 description 3
• 101150013553 CD40 gene Proteins 0.000 description 3
• 102100035793 CD83 antigen Human genes 0.000 description 3
• 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 3
• 101710205625 Capsid protein p24 Proteins 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 206010015548 Euthanasia Diseases 0.000 description 3
• 108090000331 Firefly luciferases Proteins 0.000 description 3
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 3
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 3
• 102000003814 Interleukin-10 Human genes 0.000 description 3
• 108090000174 Interleukin-10 Proteins 0.000 description 3
• 239000000232 Lipid Bilayer Substances 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 229930182555 Penicillin Natural products 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• 101710177166 Phosphoprotein Proteins 0.000 description 3
• 102100035703 Prostatic acid phosphatase Human genes 0.000 description 3
• 238000011529 RT qPCR Methods 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 206010039491 Sarcoma Diseases 0.000 description 3
• 101710149279 Small delta antigen Proteins 0.000 description 3
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
• 102100040247 Tumor necrosis factor Human genes 0.000 description 3
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 239000001506 calcium phosphate Substances 0.000 description 3
• 229910000389 calcium phosphate Inorganic materials 0.000 description 3
• 235000011010 calcium phosphates Nutrition 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 238000003501 co-culture Methods 0.000 description 3
• 238000011109 contamination Methods 0.000 description 3
• 239000012228 culture supernatant Substances 0.000 description 3
• 230000016396 cytokine production Effects 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 230000008034 disappearance Effects 0.000 description 3
• 239000002158 endotoxin Substances 0.000 description 3
• 230000002349 favourable effect Effects 0.000 description 3
• 108020001507 fusion proteins Proteins 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 230000003394 haemopoietic effect Effects 0.000 description 3
• 230000003463 hyperproliferative effect Effects 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 108091008915 immune receptors Proteins 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 230000010354 integration Effects 0.000 description 3
• 230000021633 leukocyte mediated immunity Effects 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 229920002521 macromolecule Polymers 0.000 description 3
• 208000006178 malignant mesothelioma Diseases 0.000 description 3
• 238000013411 master cell bank Methods 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 201000001441 melanoma Diseases 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 210000003071 memory t lymphocyte Anatomy 0.000 description 3
• 210000001616 monocyte Anatomy 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 230000002611 ovarian Effects 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 229940049954 penicillin Drugs 0.000 description 3
• 108010043671 prostatic acid phosphatase Proteins 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 238000003757 reverse transcription PCR Methods 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 238000012163 sequencing technique Methods 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 125000006850 spacer group Chemical group 0.000 description 3
• 238000007619 statistical method Methods 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 239000012096 transfection reagent Substances 0.000 description 3
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
• 238000002562 urinalysis Methods 0.000 description 3
• 229960005486 vaccine Drugs 0.000 description 3
• 210000003462 vein Anatomy 0.000 description 3
• 230000035899 viability Effects 0.000 description 3
• 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
• 102100039181 Ankyrin repeat domain-containing protein 1 Human genes 0.000 description 2
• 108091008875 B cell receptors Proteins 0.000 description 2
• 208000003950 B-cell lymphoma Diseases 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 238000011357 CAR T-cell therapy Methods 0.000 description 2
• 101710086403 Carbonic anhydrase-related protein Proteins 0.000 description 2
• 208000005623 Carcinogenesis Diseases 0.000 description 2
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
• 206010057248 Cell death Diseases 0.000 description 2
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
• 108091033380 Coding strand Proteins 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 241000252233 Cyprinus carpio Species 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• 101150029707 ERBB2 gene Proteins 0.000 description 2
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
• 102100039554 Galectin-8 Human genes 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
• NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
• 206010066476 Haematological malignancy Diseases 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
• 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 2
• 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 2
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
• 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
• 241000701806 Human papillomavirus Species 0.000 description 2
• 238000012404 In vitro experiment Methods 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102000013691 Interleukin-17 Human genes 0.000 description 2
• 108050003558 Interleukin-17 Proteins 0.000 description 2
• 108091092195 Intron Proteins 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 2
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
• 102000018697 Membrane Proteins Human genes 0.000 description 2
• 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
• 102000043276 Oncogene Human genes 0.000 description 2
• 208000030852 Parasitic disease Diseases 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
• 230000006052 T cell proliferation Effects 0.000 description 2
• 108010017842 Telomerase Proteins 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102100029290 Transthyretin Human genes 0.000 description 2
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
• 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
• 102000003425 Tyrosinase Human genes 0.000 description 2
• 108060008724 Tyrosinase Proteins 0.000 description 2
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 210000001015 abdomen Anatomy 0.000 description 2
• 208000019790 abdominal distention Diseases 0.000 description 2
• 238000010317 ablation therapy Methods 0.000 description 2
• 231100000230 acceptable toxicity Toxicity 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000003466 anti-cipated effect Effects 0.000 description 2
• 230000006023 anti-tumor response Effects 0.000 description 2
• 230000000840 anti-viral effect Effects 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 238000009175 antibody therapy Methods 0.000 description 2
• 239000012736 aqueous medium Substances 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 238000004166 bioassay Methods 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 229940112129 campath Drugs 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 231100000504 carcinogenesis Toxicity 0.000 description 2
• 239000013626 chemical specie Substances 0.000 description 2
• 210000000038 chest Anatomy 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 229910052804 chromium Inorganic materials 0.000 description 2
• 239000011651 chromium Substances 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 230000000875 corresponding effect Effects 0.000 description 2
• 239000003246 corticosteroid Substances 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• 230000004940 costimulation Effects 0.000 description 2
• 230000001461 cytolytic effect Effects 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
• RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 230000000763 evoking effect Effects 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 230000001605 fetal effect Effects 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 235000019152 folic acid Nutrition 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 239000012737 fresh medium Substances 0.000 description 2
• 230000005714 functional activity Effects 0.000 description 2
• 238000004362 fungal culture Methods 0.000 description 2
• 231100000025 genetic toxicology Toxicity 0.000 description 2
• 230000001738 genotoxic effect Effects 0.000 description 2
• 210000002149 gonad Anatomy 0.000 description 2
• 230000005484 gravity Effects 0.000 description 2
• 230000009931 harmful effect Effects 0.000 description 2
• 230000013632 homeostatic process Effects 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 102000027596 immune receptors Human genes 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000005917 in vivo anti-tumor Effects 0.000 description 2
• 230000000415 inactivating effect Effects 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 238000004020 luminiscence type Methods 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 238000002483 medication Methods 0.000 description 2
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
• 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 2
• 229960005489 paracetamol Drugs 0.000 description 2
• 230000005298 paramagnetic effect Effects 0.000 description 2
• 230000007918 pathogenicity Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 210000004197 pelvis Anatomy 0.000 description 2
• 210000003200 peritoneal cavity Anatomy 0.000 description 2
• 210000004303 peritoneum Anatomy 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
• 238000009101 premedication Methods 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 201000001474 proteinuria Diseases 0.000 description 2
• 230000035485 pulse pressure Effects 0.000 description 2
• 238000003908 quality control method Methods 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 230000029058 respiratory gaseous exchange Effects 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 238000010242 retro-orbital bleeding Methods 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 238000004513 sizing Methods 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 238000012430 stability testing Methods 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 238000012289 standard assay Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 230000002483 superagonistic effect Effects 0.000 description 2
• 230000008093 supporting effect Effects 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 230000009258 tissue cross reactivity Effects 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 238000003146 transient transfection Methods 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 229940116269 uric acid Drugs 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 238000012800 visualization Methods 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
• CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
• WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
• LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• 108010082808 4-1BB Ligand Proteins 0.000 description 1
• 108020005029 5' Flanking Region Proteins 0.000 description 1
• 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
• 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
• 240000003291 Armoracia rusticana Species 0.000 description 1
• 235000011330 Armoracia rusticana Nutrition 0.000 description 1
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
• 241000714230 Avian leukemia virus Species 0.000 description 1
• 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
• 108010074708 B7-H1 Antigen Proteins 0.000 description 1
• 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 108060000903 Beta-catenin Proteins 0.000 description 1
• 102000015735 Beta-catenin Human genes 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 241000283725 Bos Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
• 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 102100024210 CD166 antigen Human genes 0.000 description 1
• 102100032912 CD44 antigen Human genes 0.000 description 1
• 102100025221 CD70 antigen Human genes 0.000 description 1
• 102000004631 Calcineurin Human genes 0.000 description 1
• 108010042955 Calcineurin Proteins 0.000 description 1
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
• 108010051152 Carboxylesterase Proteins 0.000 description 1
• 102000013392 Carboxylesterase Human genes 0.000 description 1
• 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
• 241001133757 Carpentaria Species 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 102000009410 Chemokine receptor Human genes 0.000 description 1
• 108050000299 Chemokine receptor Proteins 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108091062157 Cis-regulatory element Proteins 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000004420 Creatine Kinase Human genes 0.000 description 1
• 108010042126 Creatine kinase Proteins 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
• 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
• 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
• 101710091045 Envelope protein Proteins 0.000 description 1
• 102100038595 Estrogen receptor Human genes 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 240000002989 Euphorbia neriifolia Species 0.000 description 1
• 206010051841 Exposure to allergen Diseases 0.000 description 1
• 101150064015 FAS gene Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
• 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
• 102100039717 G antigen 1 Human genes 0.000 description 1
• 101710113436 GTPase KRas Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 208000034951 Genetic Translocation Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
• BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000001398 Granzyme Human genes 0.000 description 1
• 108060005986 Granzyme Proteins 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 102100027377 HBS1-like protein Human genes 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
• 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
• 108010024164 HLA-G Antigens Proteins 0.000 description 1
• 208000001204 Hashimoto Disease Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
• 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
• 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
• 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
• 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
• 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
• 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
• 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
• 101001009070 Homo sapiens HBS1-like protein Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
• 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
• 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 1
• 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 1
• 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
• 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 1
• 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
• 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
• 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
• 101000973629 Homo sapiens Ribosome quality control complex subunit NEMF Proteins 0.000 description 1
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
• 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
• 101000671653 Homo sapiens U3 small nucleolar RNA-associated protein 14 homolog A Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
• 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
• 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
• 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
• 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
• 108010030506 Integrin alpha6beta4 Proteins 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
• 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
• 102000004556 Interleukin-15 Receptors Human genes 0.000 description 1
• 108010017535 Interleukin-15 Receptors Proteins 0.000 description 1
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 102000000704 Interleukin-7 Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 108020003285 Isocitrate lyase Proteins 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 102100034872 Kallikrein-4 Human genes 0.000 description 1
• 102100020880 Kit ligand Human genes 0.000 description 1
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
• 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
• 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• 102100033467 L-selectin Human genes 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 238000012773 Laboratory assay Methods 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 108010028275 Leukocyte Elastase Proteins 0.000 description 1
• 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 1
• 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 1
• 240000006240 Linum usitatissimum Species 0.000 description 1
• 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 1
• 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 1
• 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
• 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 1
• 102000016200 MART-1 Antigen Human genes 0.000 description 1
• 108010010995 MART-1 Antigen Proteins 0.000 description 1
• 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
• 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
• 102100025136 Macrosialin Human genes 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108090000015 Mesothelin Proteins 0.000 description 1
• 102000003735 Mesothelin Human genes 0.000 description 1
• 206010027457 Metastases to liver Diseases 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 102100034256 Mucin-1 Human genes 0.000 description 1
• 101100112779 Mus musculus Cd247 gene Proteins 0.000 description 1
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
• 241000204031 Mycoplasma Species 0.000 description 1
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
• 102000003505 Myosin Human genes 0.000 description 1
• 108060008487 Myosin Proteins 0.000 description 1
• 206010028665 Myxoedema Diseases 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 238000011887 Necropsy Methods 0.000 description 1
• 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
• 102100033174 Neutrophil elastase Human genes 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 238000002944 PCR assay Methods 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 206010034038 Parotitis Diseases 0.000 description 1
• 201000011152 Pemphigus Diseases 0.000 description 1
• 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
• 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
• 102100040120 Prominin-1 Human genes 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• 101710188315 Protein X Proteins 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 101150085390 RPM1 gene Proteins 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 208000007660 Residual Neoplasm Diseases 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 108020003564 Retroelements Proteins 0.000 description 1
• 241000712907 Retroviridae Species 0.000 description 1
• 102100022213 Ribosome quality control complex subunit NEMF Human genes 0.000 description 1
• 108091006629 SLC13A2 Proteins 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
• 102100038081 Signal transducer CD24 Human genes 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 102100037253 Solute carrier family 45 member 3 Human genes 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 208000006045 Spondylarthropathies Diseases 0.000 description 1
• 108010039445 Stem Cell Factor Proteins 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 101710145888 Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 108010002687 Survivin Proteins 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
• 101150031162 TM4SF1 gene Proteins 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 102100032802 Tetraspanin-8 Human genes 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
• 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
• 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
• 206010045240 Type I hypersensitivity Diseases 0.000 description 1
• 102100040099 U3 small nucleolar RNA-associated protein 14 homolog A Human genes 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 108010067390 Viral Proteins Proteins 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
• 101000959121 Xenopus laevis Peptidyl-alpha-hydroxyglycine alpha-amidating lyase A Proteins 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 description 1
• 229940086245 acetaminophen 650 mg Drugs 0.000 description 1
• 229960004308 acetylcysteine Drugs 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 230000004520 agglutination Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 150000001414 amino alcohols Chemical class 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000003957 anion exchange resin Substances 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 238000002841 anti-cancer assay Methods 0.000 description 1
• 230000000843 anti-fungal effect Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 229940121357 antivirals Drugs 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 239000000823 artificial membrane Substances 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 102000055104 bcl-X Human genes 0.000 description 1
• 108700000711 bcl-X Proteins 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• 239000003012 bilayer membrane Substances 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 238000010170 biological method Methods 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 229960005520 bryostatin Drugs 0.000 description 1
• MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
• MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000003710 calcium ionophore Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 101150058049 car gene Proteins 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 210000004970 cd4 cell Anatomy 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 238000011072 cell harvest Methods 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 239000002458 cell surface marker Substances 0.000 description 1
• 229940030156 cell vaccine Drugs 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 108091092356 cellular DNA Proteins 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000012829 chemotherapy agent Substances 0.000 description 1
• 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
• 208000012191 childhood neoplasm Diseases 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 238000005352 clarification Methods 0.000 description 1
• 238000011198 co-culture assay Methods 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 238000012761 co-transfection Methods 0.000 description 1
• 238000001246 colloidal dispersion Methods 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 238000009096 combination chemotherapy Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 230000037011 constitutive activity Effects 0.000 description 1
• 238000011254 conventional chemotherapy Methods 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 238000005138 cryopreservation Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 238000011500 cytoreductive surgery Methods 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 229940026692 decadron Drugs 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 229940119744 dextran 40 Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000011026 diafiltration Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• KVEAILYLMGOETO-UHFFFAOYSA-H dicalcium magnesium diphosphate Chemical compound P(=O)([O-])([O-])[O-].[Mg+2].[Ca+2].[Ca+2].P(=O)([O-])([O-])[O-] KVEAILYLMGOETO-UHFFFAOYSA-H 0.000 description 1
• 229940093541 dicetylphosphate Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
• 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 229960000284 efalizumab Drugs 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000012149 elution buffer Substances 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 108010015866 endodeoxyribonuclease NheI Proteins 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
• 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 description 1
• 201000010063 epididymitis Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 108010038795 estrogen receptors Proteins 0.000 description 1
• CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 238000011124 ex vivo culture Methods 0.000 description 1
• 238000002710 external beam radiation therapy Methods 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 201000010255 female reproductive organ cancer Diseases 0.000 description 1
• 230000008175 fetal development Effects 0.000 description 1
• 239000013020 final formulation Substances 0.000 description 1
• 229940083664 fluconazole 200 mg Drugs 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 239000012537 formulation buffer Substances 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 230000005017 genetic modification Effects 0.000 description 1
• 235000013617 genetically modified food Nutrition 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 229940029575 guanosine Drugs 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 230000005571 horizontal transmission Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 230000005745 host immune response Effects 0.000 description 1
• 230000007236 host immunity Effects 0.000 description 1
• 102000048851 human CD44 Human genes 0.000 description 1
• 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 235000020256 human milk Nutrition 0.000 description 1
• 210000004251 human milk Anatomy 0.000 description 1
• 238000011577 humanized mouse model Methods 0.000 description 1
• 230000008348 humoral response Effects 0.000 description 1
• 230000036571 hydration Effects 0.000 description 1
• 238000006703 hydration reaction Methods 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 229940010129 hydrocortisone 100 mg Drugs 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• 208000021822 hypotensive Diseases 0.000 description 1
• 230000001077 hypotensive effect Effects 0.000 description 1
• 230000005965 immune activity Effects 0.000 description 1
• 230000008004 immune attack Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 230000008073 immune recognition Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 229940088592 immunologic factor Drugs 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 238000011501 immunologic monitoring Methods 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000005918 in vitro anti-tumor Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 238000013101 initial test Methods 0.000 description 1
• 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000010212 intracellular staining Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000011462 intraperitoneal chemotherapy Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 108010024383 kallikrein 4 Proteins 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 238000001325 log-rank test Methods 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 238000007433 macroscopic evaluation Methods 0.000 description 1
• FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 239000010445 mica Substances 0.000 description 1
• 229910052618 mica group Inorganic materials 0.000 description 1
• 238000012737 microarray-based gene expression Methods 0.000 description 1
• 239000011325 microbead Substances 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000001483 mobilizing effect Effects 0.000 description 1
• 238000007479 molecular analysis Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 229940014456 mycophenolate Drugs 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 208000003786 myxedema Diseases 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 230000009965 odorless effect Effects 0.000 description 1
• 230000006508 oncogene activation Effects 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 238000006213 oxygenation reaction Methods 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 230000003094 perturbing effect Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 238000000053 physical method Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 229940081858 plasmalyte a Drugs 0.000 description 1
• 230000010287 polarization Effects 0.000 description 1
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 102000003998 progesterone receptors Human genes 0.000 description 1
• 108090000468 progesterone receptors Proteins 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 108010079891 prostein Proteins 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000002106 pulse oximetry Methods 0.000 description 1
• 238000013094 purity test Methods 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
• 229960003452 romidepsin Drugs 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 229940087854 solu-medrol Drugs 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 201000005671 spondyloarthropathy Diseases 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 230000003068 static effect Effects 0.000 description 1
• 238000011476 stem cell transplantation Methods 0.000 description 1
• 238000013190 sterility testing Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 229960002385 streptomycin sulfate Drugs 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 230000003319 supportive effect Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 101150047061 tag-72 gene Proteins 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 208000030218 transient fever Diseases 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 230000010304 tumor cell viability Effects 0.000 description 1
• 230000005740 tumor formation Effects 0.000 description 1
• 229940072651 tylenol Drugs 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 230000004222 uncontrolled growth Effects 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 230000005570 vertical transmission Effects 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 238000002689 xenotransplantation Methods 0.000 description 1